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Abstract
Background: In April 2009, the pandemic influenza A(H1N1) virus emerged and spread globally. The objective of
this study was to describe the independent risk factors for hospital mortality and the treatment effect of
corticosteroids among patients with 2009 influenza A(H1N1) infection.
Methods: We retrospectively obtained clinical data of 155 adult patients with confirmed infection of 2009
influenza A(H1N1) in 23 hospitals in Beijing, China from October 1 to December 23, 2009. Risk factors for hospital
mortality were identified with multivariate logistic regression analysis.
Results: Among the 155 patients, 90 (58.1%) were male, and mean age was 43.0 ± 18.6 years, and comorbidities
were present in 81 (52.3%) patients. The most common organ dysfunctions included acute respiratory failure,
altered mental status, septic shock, and acute renal failure. Oseltamivir was initiated in 125 patients (80.6%), only
16 patients received antiviral therapy within 48 hours after symptom onset. Fifty-two patients (33.5%) were treated
with systemic corticosteroids, with a median daily dose of 80 mg. Twenty-seven patients (17.4%) died during
hospital stay. Diabetes [odds ratio (OR) 8.830, 95% confidence interval [CI] 2.041 to 38.201, p = 0.004) and lactate
dehydrogenase (LDH) level (OR 1.240, 95% CI 1.025 to 1.500, p = 0.027) were independent risk factors of hospital
death, as were septic shock and altered mental status. Corticosteroids use was associated with a trend toward
higher hospital mortality (OR 3.668, 95% CI 0.987 to 13.640, p = 0.052).
Conclusions: Hospitalized patients with 2009 H1N1 influenza had relative poor outcome. The risk factors at
hospitalization may help clinicians to identify the high-risk patients. In addition, corticosteroids use should not be
regarded as routine pharmacologic therapy.
Background
Since the emergence of the novel 2009 influenza A
(H1N1) in March 2009 [1], the world has witnessed its
rapid and global spread to almost all countries and terri-
tories from April to June 2009 [2,3], which resulted in
the declaration of the first phase 6 global influenza pan-
d e m i cb yt h eW o r l dH e a l t hO r g a n i z a t i o n( W H O )o n
June 11, 2009 [4].
A variable proportion of patients with 2009 influenza
A(H1N1) infection were hospitalized [5]. Although
clinical manifestations and outcome of these patients
have been described, the reported cohorts often include
both inpatients and outpatients [6], or both adult and
pediatric patients [7,8], or all cases with confirmed, sus-
pected, and probable diagnoses [8-10]. The heteroge-
neous patient population in the above studies might
preclude the possibility of reporting valid risk factors for
mortality.
We report on 155 adult hospitalized patients with
confirmed infection of 2009 influenza A(H1N1) in Beij-
ing, China from October 1 to December 23, 2009. The
objective of this retrospective study was to describe the
independent risk factors for hospital mortality among
these patients. Moreover, the factors influencing
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mortality were also evaluated.
Methods
The first case of 2009 influenza A(H1N1) in mainland
China was identified on May 11, 2009 [8]. As a result,
all hospitals were required to report every case to local
health authorities and Center for Disease Control
(CDC). In this retrospective study, cases were captured
through the records in Beijing Health Bureau and Beij-
ing CDC. All hospitals with H1N1 patients were identi-
fied and contacted for possible participation into the
study. Twenty-three hospitals provided positive feed-
back, and constituted the study group.
Patients were eligible if they were (1) ≥ 18 years old;
(2) admitted to any of the 23 participating hospitals
from October 1 to December 23, 2009; (3) diagnosed as
confirmed 2009 influenza A(H1N1) infection, according
to case definitions developed by the World Health Orga-
nization [11]. Specifically, a confirmed case was defined
b yap o s i t i v er e s u l to far e a l - t i m er e v e r s e - t r a n s c r i p t a s e -
polymerase-chain-reaction (RT-PCR) assay performed at
a laboratory operated under the auspices of the Chinese
CDC [8].
Case report form was initially developed by one inves-
tigator (BD), and then cycled among all investigators for
feedback and pilot testing until consensus was reached.
All reviewers were trained during a 1.5-hour course
before the study, and then dispatched to all participating
hospitals to review case records of all eligible cases.
For all patients, the following data were recorded: sex,
age, major diagnosis, comorbidities, clinical presentation
at symptom onset and on hospital admission, major
laboratory results on hospital admission, complications,
antiviral and antibiotic treatment, supportive treatment,
and outcome. In particular, septic shock was defined
according to the consensus definition of American Col-
lege of Chest Physicians/Society of Critical Care Medi-
cine [12], while acute respiratory failure or acute renal
failure was defined if sequential organ failure assessment
score for that particular organ was greater than two
points [13].
Data were entered into a Microsoft Excel database
(Microsoft, Seattle, Wash., USA) by a data manager
(BD) under the supervision of the study steering com-
mittee (XM, YX, LJ, AL). Data were checked for incon-
sistencies and logical errors on entry, and queries were
sent to the source hospital for resolution.
The study protocol was approved by Institutional
Review Board of Beijing Fuxing Hospital (IRB-2009-
0135), and the need for informed consent was waived
because of the retrospective study design.
Values are presented as the mean ± standard deviation
or median (interquartile range) when appropriate
(continuous variables), or as a percentage of the group
from which they were derived (categorical variables).
Continuous variables were compared with the use of the
Student’s t-test or Mann-Whitney test. The chi-square
test or Fisher’s exact test was used to compare categori-
cal variables. For determination of independent predic-
tors for hospital mortality, odds ratio was estimated on
the basis of multivariate logistic regression analysis,
including exploration for robustness and interactions
using likelihood ratio tests. Two separate models using
stepwise conditional forward entry were constructed -
one for demography, comorbidities, clinical presenta-
tions, and laboratory tests on admission, and one for
complications including organ failures and infections, if
p < 0.1 in univariate analysis. Corticosteroids treatment
was forced into the first model in order to examine the
effect on patient outcome. Multivariate logistic regres-
sion analysis was also used to determine the indepen-
dent predictors of corticosteroids treatment.
The Kaplan-Meier method was used to determine the
probability of survival over the duration of follow-up
and to generate survival curves, censoring at 30 days
after symptom onset.
All comparisons were unpaired and all tests of signifi-
cance were two-tailed. A p value < 0.05 was considered
as statistically significant.
Results
Characteristics of study population
From October 1 to December 23, 2009, 562 patients
with 2009 influenza A(H1N1) infection who required
hospitalization were reported to Beijing Health Bureau,
among whom 64 patients died. Of all these patients, 287
patients were admitted into any one of the 23 participat-
ing hospitals, accounting for 51.1% of all reported cases.
After excluding 132 paediatric patients, 155 adult
patients were included in data analysis.
Among the 155 adult patients with confirmed 2009
influenza A(H1N1) infection, 90 (58.1%) were male, and
mean age was 43.0 ± 18.6 years. Eighty-one patients
(52.3%) had at least one comorbidity, including cardio-
vascular disease, chronic lung disease, diabetes, cerebral
vascular disease, and malignancy. In particular, 12
patients were pregnant women, and 2 patients were
postpartum women (Table 1).
The most common presenting symptom was fever
(> 37.8°C) (93.5%), followed by cough (91.6%), dyspnea
(47.1%), sore throat (29.7%), and myalgia (17.4%). The
median time from symptom onset to hospital admission
was 5 days. On hospital admission, 82 patients (52.9%)
still complained dyspnea, and 129 patients (83.2%) were
diagnosed as pneumonia according to chest X-ray. Forty
of 141 patients (28.4%) who were tested had leukopenia
(white cell count < 4.0 × 10
9/L), while 19 patients
Xi et al. BMC Infectious Diseases 2010, 10:256
http://www.biomedcentral.com/1471-2334/10/256
Page 2 of 8(13.5%) had leukocytosis (white cell count > 10.0 × 10
9/
L), and 53 of 125 patients (42.4%) had lymphopenia
(lymphocyte count < 0.8 × 10
9/L). Laboratory tests also
suggested mild to moderately increased cardiac enzymes,
liver enzymes, and total bilirubin (Table 1). Of 126
patients who were tested, 74 patients (58.7%) had ele-
vated level of lactate dehydrogenase (LDH) (> 270 U/L).
Alanine transaminase and aspartate transaminase were
elevated in 32 of 111 (28.8%) and 69 of 115 (60.0%)
patients, respectively.
Table 1 Hospitalized adult patients with 2009 Influenza A (H1N1) in Beijing: demographics, comorbidities, and clinical
presentation
Survivor
(n = 128)
Nonsurvivor
(n = 27)
Total
(n = 155)
P value
Male sex 73 (57.0%) 17 (63.0%) 90 (58.1%) 0.570
Age, year 42.4 ± 18.2 45.9 ± 20.7 43.0 ± 18.6 0.388
Ethnicity
Han Chinese 127 (99.2%) 25 (92.6%) 152 (98.1%) 0.079
Smoker 28 (21.9%) 7 (25.9%) 35 (22.6%) 0.647
No comorbidity 60 (46.9%) 14 (51.9%) 74 (47.7%) 0.609
Comorbidity
Cardiovascular disease 34 (26.6%) 11 (40.7%) 45 (29.0%) 0.140
Hypertension 25 (19.5%) 10 (37.0%) 35 (22.6%) 0.048
Ischemic heart disease 19 (14.9%) 5 (18.5%) 24 (15.5%) 0.572
Chronic lung disease 19 (14.9%) 3 (11.1%) 22 (14.2%) 0.768
COPD 8 (6.3%) 2 (7.4%) 10 (6.5%) 0.686
Diabetes 13 (10.2%) 7 (25.9%) 20 (12.9%) 0.051
Pregnancy or postpartum 12 (9.4%) 2 (7.4%) 14 (9.0%) 1.000
Pregnancy 11 (8.6%) 1 (3.7%) 12 (7.7%) 0.693
Postpartum < 1 month 1 (0.8%) 1 (3.7%) 2 (1.3%) 0.319
Cerebral vascular disease 6 (4.7%) 3 (11.1%) 9 (5.8%) 0.191
Symptoms at disease onset
Fever (> 37.8°C) 121 (94.5%) 24 (88.9%) 145 (93.5%) 0.380
Cough 117 (91.4%) 25 (92.6%) 142 (91.6%) 1.000
Dyspnea 56 (43.8%) 17 (63.0%) 73 (47.1%) 0.069
Sore throat 42 (32.8%) 4 (14.8%) 46 (29.7%) 0.063
Myalgia 24 (18.8%) 3 (11.1%) 27 (17.4%) 0.416
Rhinorrhea 21 (16.4%) 3 (11.1%) 24 (15.5%) 0.770
Hemoptysis 15 (11.7%) 4 (14.8%) 19 (12.3%) 0.746
Diarrhea 6 (4.7%) 1 (3.7%) 7 (4.5%) 1.000
Vomiting 5 (3.9%) 0 5 (3.2%) 0.588
Time from symptoms to hospital admission, day* 5.0 (3.0, 7.0) 6.0 (3.5, 7.0) 5.0 (3.0, 7.0) 0.376
Clinical presentation on admission
Dyspnea 61 (47.7%) 21 (77.8%) 82 (52.9%) 0.004
Pneumonia on CXR 104 (81.3%) 25 (92.6%) 129 (83.2%) 0.254
Laboratory tests on admission
White cell count, 10
9/L 6.1 ± 3.7 7.3 ± 5.1 6.3 ± 4.0 0.183
Lymphocyte, 10
9/L 1.2 ± 1.4 0.7 ± 0.3 1.1 ± 1.3 0.118
CPK, U/L 339 ± 620 538 ± 548 373 ± 610 0.222
CK-MB, μg/L 23 ± 33 29 ± 22 24 ± 31 0.457
cTnI, μg/L 0.16 ± 0.23 0.32 ± 0.69 0.21 ± 0.43 0.417
LDH, U/L 356 ± 240 744 ± 759 432 ± 422 0.041
Total bilirubin, μmol/L 20.2 ± 57.8 48.8 ± 156.6 25.8 ± 86.2 0.431
AST, U/L 57 ± 49 348 ± 803 113 ± 366 0.105
ALT, U/L 51 ± 111 123 ± 254 65 ± 152 0.209
ALT, alanine transaminase; AST, aspartate transaminase; CK-MB, creatine kinase-MB; COPD, chronic obstructive pulmonary disease; CPK, creatine phosphokinase;
cTnI, cardiac troponin I; CXR, chest-X ray; LDH, lactate dehydrogenase
*expressed as median (interquartile range)
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Of all patients, 125 (80.6%) were treated with oseltami-
vir, although only 16 patients (10.3%) received antiviral
therapy within 48 hours after symptom onset (Table 2).
Broad-spectrum antibiotics were prescribed in 139
(89.7%) patients as empiric or definitive therapy.
The most common organ failures during hospital stay
included acute respiratory failure (40.0%), altered mental
status (12.9%), septic shock (11.6%), and acute renal fail-
ure (9.7%). Forty-three patients (27.7%) were treated
with invasive mechanical ventilation, while noninvasive
mechanical ventilation was used in 32 patients (20.6%).
Vasopressors and inotropes were used in 28 (18.1%) and
9 (5.8%) patients, respectively.
Fifty-two patients (33.5%) were treated with systemic
corticosteroids. Daily dose of corticosteroids ranged
from methylprednisolone 12 mg to 320 mg (or equiva-
lent dose), with a median dose of 80 mg (interquartile
range, 80 mg to 160 mg).
Outcome and risk factors
Twenty-seven patients (17.4%) died during hospital stay,
all within 28 days after admission (Figure 1). Causes of
death included multiple organ failure (n = 14), refrac-
tory circulatory shock (n = 6), refractory respiratory fail-
ure (n = 5), and others (n = 2).
Compared with survivors, more nonsurvivors had
hypertension (37.0% vs. 19.5%, p = 0.048). On hospital
admission, nonsurvivors were more likely to be dyspneic
(77.8% vs. 47.7%, p = 0.004), and lactate dehydrogenase
(LDH) level was significantly higher (744 ± 759 vs. 356
± 240 U/L, p = 0.041) (Table 1). During hospitalization,
more nonsurvivors developed organ failure (acute
respiratory failure, altered mental status, septic shock,
and acute renal failure) and secondary infections (Table
2). Therefore, nonsurvivors were more likely to be trea-
ted with vasoactive agents, mechanical ventilation, and
continuous renal replacement therapy (Table 2).
Risk factors for hospital mortality by multivariate
logistic regression analysis included diabetes (odds ratio
Table 2 Hospitalized adult patients with 2009 Influenza A (H1N1) in Beijing: complications, definitive treatment, and
supportive treatment
Survivor
(n = 128)
Nonsurvivor
(n = 27)
Total
(n = 155)
P value
Complications
Acute respiratory failure 39 (30.5%) 23 (85.2%) 62 (40.0%) 0.003
Septic shock 1 (0.8%) 17 (63.0%) 18 (11.6%) < 0.001
Acute renal failure 4 (3.1%) 11 (40.7%) 15 (9.7%) < 0.001
Altered mental status 6 (4.7%) 14 (51.9%) 20 (12.9%) < 0.001
Bacterial pneumonia 15 (11.7%) 13 (48.1%) 28 (18.1%) < 0.001
Bloodstream infection 0 3 (11.1%) 3 (1.9%) 0.006
Other infections 0 5 (18.5%) 5 (3.2%) < 0.001
Antiviral agents 107 (83.6%) 25 (92.6%) 132 (85.2%) 0.371
Oseltamivir treatment 101 (78.9%) 24 (88.9%) 125 (80.6%) 0.259
within 48 hrs of symptom onset 12 (9.4%) 4 (14.8%) 16 (10.3%) 0.507
Broad-spectrum antibiotics 113 (88.3%) 26 (96.3%) 139 (89.7%) 0.309
Corticosteroids 35 (27.4%) 17 (63.0%) 52 (33.5%) < 0.001
Vasopressors 5 (3.9%) 23 (85.2%) 28 (18.1%) < 0.001
Inotropes 2 (1.6%) 7 (25.9%) 9 (5.8%) < 0.001
Neuromuscular blockade 1 (0.8%) 7 (25.9%) 8 (5.2%) < 0.001
Noninvasive ventilation 19 (14.9%) 13 (48.1%) 32 (20.6%) < 0.001
Invasive ventilation 19 (14.9%) 24 (88.9%) 43 (27.7%) < 0.001
Continuous renal replacement therapy 4 (3.1%) 13 (48.1%) 17 (11.0%) < 0.001
Figure 1 Kaplan-Meier survival curve of hospitalized patients
with 2009 influenza A (H1N1) infection. (Dash lines represent
95% confidence interval).
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Page 4 of 8[OR] 8.830, 95% confidence interval [CI] 2.041 to
38.201, p = 0.004), and lactate dehydrogenase level (per
100 U/L increase) (OR 1.240, 95% CI 1.025 to 1.500,
p = 0.027) (Table 3).
Oseltamivir treatment did not result in significant
improvement in patient outcome (Table 2). Among 125
patients treated with oseltamivir, initiation of antiviral ther-
apy within 48 hours of symptom onset showed no influ-
ence on hospital mortality (4/16 vs. 20/109, p = 0.508).
Corticosteroids treatment
Corticosteroids treatment was associated with a trend
toward higher hospital mortality (OR 3.668, 95% CI
0.987 to 13.640, p = 0.052) (Table 3). However, corticos-
teroids were used in more critically ill patients, as shown
in Table 4. LDH level on hospital admission and acute
respiratory failure were independent predictors of corti-
costeroids treatment (Table 4). Moreover, patients trea-
ted with a lower daily dose of corticosteroids (≤ 80 mg
methylpredisolone or equivalent dose) exhibited a simi-
lar mortality rate compared with those treated with
higher daily dose (9/30 vs. 8/22, p = 0.854). Subgroup
Table 3 Hospitalized adult patients with 2009 Influenza A
(H1N1) in Beijing: risk factor for hospital mortality by
logistic regression analysis
OR 95%CI P
Model 1
Diabetes 8.830 2.041 - 38.201 0.004
LDH on admission, per 100 U/L
increase
1.240 1.025 - 1.500 0.027
Corticosteroids treatment 3.668 0.987 - 13.640 0.052
Model 2
Septic shock 143.039 10.355 -
1975.8
<
0.001
Altered mental status 8.482 1.760 - 40.887 0.008
Acute respiratory failure 9.982 0.947 -
105.240
0.056
CI, confidence interval; LDH, lactate dehydrogenase; OR, odds ratio
Variables included in model 1: ethnicity, comorbidity (hypertension, diabetes),
symptoms at disease onset (dyspnea, sore throat), clinical presentation on
admission (dyspnea), laboratory test on admission (lactate dehydrogenase),
and corticosteroids treatment.
Variables included in model 2: complications (acute respiratory failure, septic
shock, acute renal failure, altered mental status, bacterial pneumonia,
bloodstream infection, other infections)
Table 4 Comparison of patients treated with and without corticosteroids
No corticosteroids
(n = 103)
Corticosteroids
(n = 52)
Univariate analysis
OR (95%CI)
Multivariate analysis
OR (95%CI)
Comorbidity
Cardiovascular diseases 35 10 0.463 (0.208 - 1.031)
Chronic lung diseases 20 2 0.116 (0.037 - 0.740)
Symptoms at disease onset
Dyspnea 40 33 2.736 (1.373 - 5.452)
Hemoptysis 9 10 2.487 (0.942 - 6.568)
On hospital admission
Dyspnea 42 40 4.841 (2.275 - 10.304)
Pneumonia on CXR 81 48 3.259 (1.060 - 10.025)
Laboratory tests on admission
CPK 260 ± 447 577 ± 795 1.001 (1.000 - 1.002)
CK-MB 20 ± 30 32 ± 33 1.014 (0.997 - 1.032)
LDH, per 100 U/L increase 305 ± 229 658 ± 572 1.508 (1.219 - 1.866) 1.401 (1.107 - 1.773)
Complications
Acute respiratory failure 24 (23.3%) 38 (73.1%) 8.935 (4.160 - 19.187) 8.738 (2.504 - 30.489)
Septic shock 5 (4.9%) 13 (25.0%) 6.533 (2.183 - 19.551)
Acute renal failure 5 (4.9%) 10 (19.2%) 4.667 (1.503 - 14.486)
Altered mental status 9 (8.7%) 11 (21.2%) 2.842 (1.093 - 7.390)
Bloodstream infection 0 3 1.061 (0.992 - 1.135)
Other infections 1 4 8.500 (0.925 - 78.106)
Supportive treatment
Vasopresssors 9 19 6.013 (2.478 - 14.596)
Neuromuscular blockade 1 7 15.867 (1.896 - 132.776)
Noninvasive ventilation 11 21 5.666 (2.467 - 13.063)
Invasive ventilation 16 27 5.873 (2.742 - 12.578)
CK-MB, creatine kinase-MB; CPK, creatine phosphokinase; CXR, chest-X ray; LDH, lactate dehydrogenase
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associated with higher hospital mortality rate in patients
without acute renal failure (10/42 vs. 6/98, p = 0.0064)
or altered mental status (8/41 vs. 5/94, p = 0.0242), and
in patients with bacterial pneumonia (9/11 vs. 4/17,
p = 0.0085). There was no systemic treatment effect on
hospital mortality of either lower or higher daily dose of
corticosteroids compared with no corticosteroids treat-
ment (Additional file 1, Table S1).
No interaction between corticosteroids treatment and
any complications (including acute respiratory failure,
septic shock, acute renal failure, altered mental status,
bacterial pneumonia, bloodstream infection, and other
infections) or oseltamivir treatment was found.
Discussion
In this retrospective study of hospitalized adult patients
with confirmed infection of 2009 influenza A(H1N1), we
have found that diabetes, serum level of LDH on hospi-
tal admission, septic shock, and altered mental status
were independent predictors of hospital mortality. In
addition, corticosteroids treatment is associated with a
trend towards worse outcome, although it is more likely
to be used in critical illness, as shown by an elevated
LDH level and the presence of acute respiratory failure.
The mortality seen in our study is significantly higher
than those of hospitalized patients in the United States
[7], United Kingdom [14], and Australia [15]. The later
studies often summarized the initial hospitalized patients
in each country, when even mild cases were admitted
due to uncertainty of disease progression and prognosis.
In contrary, the patients in our study developed the ill-
ness about 5 months after the first case of 2009 influ-
enza A(H1N1) in China [8], when only high-risk
patients were hospitalized, while most mild cases were
followed up in fever clinics. The above difference in
admission policy may be reflected by the significantly
longer median time from symptom onset to hospital
admission (5 vs. 2 to 3 days), the higher proportion of
patients with signs of pneumonia on Chest X-ray (83.2%
vs. 29 to 40%), and the higher mortality rate in our
study, which is similar to those observed in patients
requiring intensive care support in Australia [16] and
Canada [10].
Almost half of the 155 hospitalized patients in our
analysis do not have any comorbidities. The absence of
serious comorbidities emphasizes that young, relatively
healthy adults were the primary population affected by
2009 influenza A(H1N1) infection. On the contrary,
underlying medical conditions associated with complica-
tions from seasonal influenza have been consistently
shown as risk factors for hospital admission [17], inten-
sive care unit (ICU) admission [18,19], and death
[17,19,20]. The commonly acknowledged comorbidities
may be classified according to chronic medical condi-
tions recognized by the Advisory Committee on Immu-
nization Practices, including cardiovascular disease,
pulmonary disease, liver disease, cancer, and diabetes
[17]. Diabetes and stress-induced hyperglycemia are
known to be associated with an increased risk of com-
plications and death among critically ill patients [21]. In
this study, when infected with 2009 influenza A(H1N1),
patients with diabetes were at a higher risk of death,
compared with those without diabetes. In a cohort of
1479 patients admitted to hospital with laboratory-con-
firmed pandemic (H1N1) influenza in Canada, Campbell
reported that the risk of a severe outcome (including
death and ICU admission) was greatest among patients
with diabetes (relative risk 2.2, 95%CI 1.7 - 2.7) [18].
Likewise, when comparing 1266 hospitalized patients
with the general population in France, Hanslik also
found that diabetes was significantly associated with
death (OR 3.5, 95%CI 2.5 - 5.1) [19].
Patients with increased serum level of LDH on hospi-
tal admission are at a higher risk of death during hospi-
talization. This is not a surprising finding, because, as a
non-specific enzyme found ubiquitously in cells, the
increased serum level of LDH probably indicates the
degree of tissue necrosis, and hence the severity of the
viral infection as well as pneumonia. The association of
high level of LDH and severity of illness, or even death,
although not found in patients with 2009 influenza A
(H1N1), has been widely reported in patients with
severe acute respiratory syndrome (SARS). For example,
high LDH level on hospital admission was associated
with development of acute respiratory distress syndrome
[22], and death during hospital stay [23,24].
It is recommended that therapy with a neuraminidase
inhibitor is especially important for patients with under-
lying risk factors and those with severe or progressive
clinical illness [25]. However, we did not observe any
treatment effect of oseltamivir in our analysis. Only 16
out of 155 patients (10.3%) in our study received oselta-
mivir treatment within 48 hours after symptom onset.
In comparison, Jain and Louie found that early antiviral
therapy was administered in 39% and 51% of patients,
respectively [7,26]. Studies have shown that delayed
antiviral treatment is associated with high risk of pro-
gression to severe disease such as ICU admission and
respiratory failure, prolonged hospital stay, and even
death [25,27]. It is also possible that the delay in anti-
viral treatment in our patients resulted in higher hospi-
tal mortality (17.4%) compared with the subgroup of
adult hospitalized patients with 2009 influenza A(H1N1)
in the United States [7,26].
Corticosteroids remain a controversy in the treat-
ment of viral infection [28]. WHO strongly recom-
mends that systemic corticosteroids should not be
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an approved research protocol [29]. In a retrospective
study of 78 consecutive adult SARS patients, corticos-
teroids treatment was associated with a 20.7-fold
increase in either ICU admission or mortality, indepen-
dent of age and disease severity [30]. Liem et al also
found that corticosteroids treatment was an indepen-
dent risk factor of death in human H5N1 influenza A
infection [31]. Observational studies demonstrated that
corticosteroid use was associated with slower viral
clearance, significantly increased odds of persistent
viral replication 7 days after symptom onset [32], and
a longer duration of viral shedding with increased cor-
ticosteroid dose [33]. In patients with 2009 influenza A
(H1N1) infection, Jain et al found that steroids were
more commonly used in patients with severe outcome
compared with those without severe outcome (52% vs.
31%, p < 0.05) [7]. Our data suggested that clinicians
tend to use corticosteroids in more critically ill
patients, such as patients with elevated LDH level or
acute respiratory failure. However, even after adjusted
for these confounding factors, results of logistic regres-
sion analysis still indicated a trend towards fatal out-
come associated with corticosteroid use.
Our study is subject to several limitations. Case cap-
ture was based on passive reporting by clinicians, and
underreporting may have occurred because of poor
recognition and the lack of specificity of clinical pre-
sentations. The retrospective nature of this study pre-
cluded the possibility of integrating body mass index
into our regression analysis model, as height and
weight data were not routinely documented in most
cases. However, the effect of underlying medical condi-
tions and morbid obesity may not be independent. For
example, diabetes is reportedly up to seven times more
prevalent in obese persons [34], so that the diabetic
cases were most likely among obese patients. The rela-
tively large odds ratio for diabetes for hospital mortal-
ity in our study suggests an additional risk compared
to obesity alone.
Conclusions
We have found that hospitalized patients with 2009
influenza A(H1N1) have relatively poor outcome. Dia-
betes and elevated LDH level on hospital admission, as
well as the presence of septic shock and altered mental
status, represent independent risk factors for hospital
death among these patients. Early recognition of these
risk factors may help clinicians to identify the high-risk
patients. In addition, corticosteroids use should not be
regarded as routine pharmacologic therapy, although
this may need confirmation by further large scale pro-
spective study.
Additional material
Additional file 1: Supplementary table S1. Table to show subgroup
analysis of the effect of corticosteroids treatment on hospital mortality.
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